followed by Eli Lillys drug Mounjaro, FDA approved to treat Diabetes in 2022
These include nausea, vomiting, diarrhoea, abdominal pain, and constipation, which typically occur during dose initiation or escalation and often diminish over time as the body adjusts to the medication
This can lead to oxidative stress and an increased risk of chronic disease
GLP-1 receptor agonists available in the UK include: Semaglutide : Ozempic (for type 2 diabetes), Wegovy (for weight management), and Rybelsus (oral formulation for type 2 diabetes) Dulaglutide (Trulicity) for type 2 diabetes Liraglutide : Victoza (for type 2 diabetes), Saxenda (for weight management) Exenatide (Byetta) for type 2 diabetes Most GLP-1 receptor agonists are administered via subcutaneous injection , with dosing frequencies varying from twice daily to once weekly depending on the specific formulation
Complete checkout to access our secure intake form and share your information with our licensed practitioners
Photoprotection: against UVB, UVA, UVA1, + blue light